ADVANCED VIRAL RESEARCH ANNOUNCES RESULTS OF WOUND-HEALING STUDY

Advanced Viral Research has announced that an animal study of the topical application of AVR 118 has shown that the drug accelerates the rate at which wounds heal. Although preliminary, these studies provide the rationale for advancing AVR 118 to the human testing stage.

AVR118 represents a new class of complex cytoprotective agents that target, among other things, body-wasting (cachexia) disorders. AVR118 has also shown to have topical wound healing properties.

Degenerative conditions associated with body wasting, such as cancer, HIV/AIDS and chronic inflammation, are potential disease targets for AVR118 therapy.